Not really, had 120 million volume yesterday
But volume is far about average and chart is building!
Many big institutional investors, plus company insiders holding big positions.
But volume is far about average and chart is building!
Many big institutional investors, plus company insiders holding big positions.
Recent SVRA News
- Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference • Business Wire • 05/27/2026 08:05:00 PM
- Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 • Business Wire • 05/20/2026 12:15:00 PM
- Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 05/19/2026 06:15:00 PM
- Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 05/18/2026 06:55:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 08:05:39 PM
- Savara Reports First Quarter Financial Results and Provides Business Update • Business Wire • 05/12/2026 08:05:00 PM
- Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference • Business Wire • 05/11/2026 08:05:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 08:26:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:24:46 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:22:42 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 04/17/2026 08:05:00 PM
- Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 04/15/2026 08:05:00 PM
- Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference • Business Wire • 04/14/2026 12:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/10/2026 08:18:47 PM
- Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 04/07/2026 12:05:00 PM
- Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 03/30/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:16:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 12:30:15 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2026 12:10:55 PM
- Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update • Business Wire • 03/13/2026 12:05:00 PM
- Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 03/06/2026 09:05:00 PM
- Savara Announces Participation in 2026 Citizens Life Sciences Conference • Business Wire • 03/04/2026 09:05:00 PM
- Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) • Business Wire • 02/20/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:30:13 PM
